Etomidate as anesthetic agent in asthmatic child with food allergy
Department of Anaesthesia, General Hospital of Larisa, Greece.
Case Study
GSC Advanced Research and Reviews, 2024, 19(01), 001–003.
Article DOI: 10.30574/gscarr.2024.19.1.0125
Publication history:
Received on 23 February 2024; revised on 30 March 2024; accepted on 02 April 2024
Abstract:
Children with bronchial asthma and respiratory infections have significant peri-operative implications for the anaesthesiologists. With improvements in medical knowledge and anaesthesia techniques, morbidity and mortality associated with an asthmatic child undergoing surgery have come down. Etomidate is an intravenous anesthetic agent whose clinical effects are the result of potentiation of the gamma-amino butyric acid inhibitory neurotransmitter system with the alteration of transmembrane chloride conductance. Physicians commonly use etomidate for adult rapid-sequence intubation, but the manufacturer does not recommend its use for children under 10 years of age due to a lack of data. Ketamine has been suggested as an alternative agent given its limited effects on hemodynamic function related to the release of endogenous catecholamines. A child aged 11 years and weighing 40 kg, with egg allergy and a more general allergic predisposition, with a history of asthma treated with inhalants and a recent respiratory infection with antibiotics, came with a diagnosis of acute abdomen. Etomidate was used as an anesthetic agent in combination with ketamine, using rocuronium and sevoflurane. Corticosteroids and aminophylline were given to prevent bronchospasm. Ketamine and etomidate, both of which provide effective sedation with limited effects on hemodynamic function, have become increasingly popular as induction agents.
Keywords:
Etomidate; Ketamine; Allergic; Astma; Child; Intubation
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
